Z
Zelig Eshhar
Researcher at Tel Aviv Sourasky Medical Center
Publications - 187
Citations - 12375
Zelig Eshhar is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 58, co-authored 187 publications receiving 11428 citations. Previous affiliations of Zelig Eshhar include Tel Aviv University & Weizmann Institute of Science.
Papers
More filters
Journal ArticleDOI
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
TL;DR: This work designed and constructed chimeric genes composed of a single-chain Fv domain of an antibody linked with gamma or zeta chains, the common signal-transducing subunits of the immunoglobulin receptor and the TCR, which could be expressed as functional surface receptors in a cytolytic T-cell hybridoma.
Journal ArticleDOI
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
TL;DR: This chimeric receptor provides the T cell with an antibody-like specificity and is able to effectively transmit the signal for T-cell activation and execution of its effector function.
Journal ArticleDOI
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw,Michael H. Kershaw,Michael H. Kershaw,Jennifer A. Westwood,Jennifer A. Westwood,Linda L. Parker,Gang Wang,Gang Wang,Zelig Eshhar,Sharon Mavroukakis,Donald E. White,John R. Wunderlich,Silvana Canevari,Linda Rogers-Freezer,Clara C. Chen,James Chih-Hsin Yang,Steven A. Rosenberg,Patrick Hwu +17 more
TL;DR: Large numbers of gene-modified tumor-reactive T cells can be safely given to patients, but these cells do not persist in large numbers long term, and future studies need to employ strategies to extend T cell persistence.
Journal ArticleDOI
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
Yangbing Zhao,Qiong J. Wang,Shicheng Yang,James N. Kochenderfer,Zhili Zheng,Xiaosong Zhong,Michel Sadelain,Zelig Eshhar,Steven A. Rosenberg,Richard A. Morgan +9 more
TL;DR: PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model.
Journal Article
In Vivo Antitumor Activity of T Cells Redirected with Chimeric Antibody/T-Cell Receptor Genes
Patrick Hwu,James Chih-Hsin Yang,R Cowherd,J. Treisman,G. E. Shafer,Zelig Eshhar,Steven A. Rosenberg +6 more
TL;DR: It is shown that T cells can be gene modified to react in vivo against tumor antigens, defined by mAbs, which is potentially applicable to a number of neoplastic and infectious diseases and may allow adoptive immunotherapy against types of cancer not previously amenable to cellular immunotherapy.